<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02537002</url>
  </required_header>
  <id_info>
    <org_study_id>B2341003</org_study_id>
    <nct_id>NCT02537002</nct_id>
  </id_info>
  <brief_title>Single Dose Study of PF-05230907 in Healthy Japanese Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-blind, Sponsor-open, Placebo-controlled, Single Ascending Dose Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of An Intravenous Bolus Infusion Pf-05230907 In Healthy Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is the following:

        -  To determine the safety and tolerability of single ascending intravenous (IV) doses of
           PF-05230907 in healthy Japanese subjects.

        -  To characterize the PK profile of single ascending IV doses of PF-05230907 in healthy
           Japanese subjects.

        -  To characterize the PD profiles of single ascending IV doses of PF-05230907 in healthy
           Japanese subjects.

        -  To evaluate the immunogenicity of PF-05230907 in healthy Japanese subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events and Serious Adverse Events Per Participant of PF-05230907</measure>
    <time_frame>up to 2 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose Time to Reach maximum Observed Plasma Concentration (Tmax) of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Plasma Decay Half-Life (t1/2) of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose steady state Volume of Distribution (Vss) of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose clearance (CL) of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Maximum Observed plasma concentration (Cmax) of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (last)]of PF-05230907</measure>
    <time_frame>Minute 0, 2, 5, 15, 40, 60 minute post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of aPTT from pre-dose to post-dose</measure>
    <time_frame>Hour 0, 24 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of prothrombin fragments 1+2 (PF1+2)</measure>
    <time_frame>Hour 0, 24 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of plasma D-dimer</measure>
    <time_frame>Hour 0, 48 hour post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of anti-drug antibody (ADA)</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of development of neutralizing antibody (NAb)</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of factor X activity</measure>
    <time_frame>up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1- PF-05230907 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2- PF-05230907 or Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>A single intravenous dose of 3 μg/kg</description>
    <arm_group_label>Cohort 1- PF-05230907 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-05230907</intervention_name>
    <description>A single intravenous dose of 5 μg/kg</description>
    <arm_group_label>Cohort 2- PF-05230907 or Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>A single intravenous dose of matched placebo</description>
    <arm_group_label>Cohort 1- PF-05230907 or Placebo</arm_group_label>
    <arm_group_label>Cohort 2- PF-05230907 or Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male of females

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs)
             and &lt;120 kg (265 lbs).

          -  Japanese subjects who have four biologic Japanese grandparents born in Japan.

        Exclusion Criteria:

          -  Pregnant or nursing females.

          -  Females of childbearing potential who are unwilling or unable to use an acceptable
             method of contraception.

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511-5473</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B2341003&amp;StudyName=A%20Phase%201%2C%20Randomized%2C%20Double-blind%2C%20Sponsor-open%2C%20Placebo-controlled%2C%20Single%20Ascending%20Dose%20Study%20To%20Evaluate%20The%20Safety%2C%20Tolerability%2C%20Pharmacokinetics%20And%20Pharmacodynamics%20Of%20An%20Intravenous%20Bolus%20Infusion%20Pf-05230907%20In%20Healthy%20Japanese%20Subjects</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2015</study_first_submitted>
  <study_first_submitted_qc>August 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2015</study_first_posted>
  <last_update_submitted>April 28, 2016</last_update_submitted>
  <last_update_submitted_qc>April 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PF-05230907</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamic</keyword>
  <keyword>Immunogenicity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

